Stock AnalizIDEXX Laboratories (IDXX) earnings for the quarter ended September 2026: EPS beats estimates
IDEXX Laboratories reported results for the quarter ended September 2026 on November 2, 2026. Adjusted earnings per share came in at $4.01 against the analysts’ average forecast of $3.71, a beat of 8.0%.
Revenue for the quarter was $1.21 billion, up 9.9% from $1.11 billion in the same quarter a year earlier.
The market’s verdict: the stock rose 21.9% on the first trading day after the report.
The last four quarters
IDEXX Laboratories has beaten the analysts’ EPS forecast in 4 of the last 4 quarters.
| Quarter | EPS | Forecast | Surprise | Revenue growth | Price reaction |
|---|---|---|---|---|---|
| Sep 2026 | $4.01 | $3.71 | +8.0% | +10% | +21.9% |
| Jun 2026 | $4.27 | $3.93 | +8.5% | +10% | +3.0% |
| Mar 2026 | $3.47 | $3.41 | +1.7% | +14% | +2.9% |
| Dec 2025 | $3.08 | $2.94 | +4.8% | +14% | −5.7% |
What comes next
Analysts expect EPS of $3.32 for the next quarter on average and $15.00 for the fiscal year ending December 31, 2026.
The average analyst price target is $717.17, 2% above the current price of $704.23.
Valuation and score
IDEXX Laboratories scores 3.4 out of 5 overall on Stock Analiz (good, with some weak spots), trades at a trailing P/E of about 47.5, and its intrinsic value under moderate assumptions is about 63% below the current market value. Full IDEXX Laboratories analysis with 10 years of financials
Frequently asked questions
What was IDEXX Laboratories’s EPS for the quarter ended September 2026?
$4.01 adjusted per share, against an analyst consensus of $3.71.
How much revenue did IDEXX Laboratories report?
$1.21 billion, up 9.9% year over year.
More
This report was written automatically from the published numbers within hours of the release. It is information, not investment advice.